Israel - anglès - Ministry of Health

teva israel ltd - atazanavir as sulfate - capsules - atazanavir as sulfate 200 mg - atazanavir - atazanavir teva ® is indicated in combination with other antiretroviral agents for for the treatment of hiv-1 infection.

Israel - anglès - Ministry of Health

teva israel ltd - atazanavir as sulfate - capsules - atazanavir as sulfate 300 mg - atazanavir - atazanavir teva ® is indicated in combination with other antiretroviral agents for for the treatment of hiv-1 infection.

Estats Units - anglès - NLM (National Library of Medicine)

remedyrepack inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 300 mg - reyataz ® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: - reyataz is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. - use of reyataz/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . reyataz is contraindicated:reyataz is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of reyataz capsules or reyataz oral powder [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or lif

Estats Units - anglès - NLM (National Library of Medicine)

remedyrepack inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 200 mg - reyataz ® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: - reyataz is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. - use of reyataz/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . reyataz is contraindicated:reyataz is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of reyataz capsules or reyataz oral powder [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or lif

Estats Units - anglès - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: -   atazanavir capsules are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. -   use of atazanavir/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . atazanavir is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are asso

Estats Units - anglès - NLM (National Library of Medicine)

cipla usa inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. limitations of use: - atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus.[see use in specific populations (8.4)] . - use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . atazanavir is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concen

Estats Units - anglès - NLM (National Library of Medicine)

remedyrepack inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. limitations of use: - atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. [see use in specific populations ( 8.4)] . - use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology ( 12.4)] . atazanavir is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - atazanavir sulfate 170.872mg (equiv 150 mg atazanavir) - capsule - 150 mg - active: atazanavir sulfate 170.872mg (equiv 150 mg atazanavir) excipient: crospovidone gelatin indigo carmine lactose monohydrate magnesium stearate titanium dioxide - atazanavir is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - atazanavir sulfate 227.829mg (equiv 200 mg atazanavir) - capsule - 200 mg - active: atazanavir sulfate 227.829mg (equiv 200 mg atazanavir) excipient: crospovidone gelatin indigo carmine lactose monohydrate magnesium stearate titanium dioxide - atazanavir is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - atazanavir sulfate 341.744mg (equiv 300 mg atazanavir) - capsule - 300 mg - active: atazanavir sulfate 341.744mg (equiv 300 mg atazanavir) excipient: crospovidone gelatin indigo carmine iron oxide red iron oxide yellow lactose monohydrate magnesium stearate titanium dioxide - atazanavir is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.